Balaxi Pharmaceuticals
- Market cap
- ₹ 112 Cr.
- P/E
- 46.2x
- P/B
- 0.46x
- 52-week range
- 15.2 – 43.85
- ROE
- 1%
- ROCE
- 3%
- Dividend yield
- 0%
- Debt / equity
- 0.23
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE
About
Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across the Americas, Africa and the Caribbean islands. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It is engaged in International Wholesale Distribution of Pharmaceuticals. The Company’s products include Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents, and Laxative. Its Boadent brand includes anticavity dental toothpaste. Its subsidiaries are Balaxi Global DMCC, Dubai and Balaxi healthcare Ecuador.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Balaxi Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)46.2 against a typical 34.3: pricier than most peers (1st = cheapest).149th of 220
- Sales growth+14.1% against a typical +15.6% from a year earlier.104th of 197
- Profit growth+348.3% against a typical +18.9% from a year earlier.13th of 160
- Share price, 3 months−16.1% against a typical −0.5%.168th of 200
- Size₹ 111.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).144th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BBB by CRISIL- CRISIL lowered its rating on 1 Apr 2026.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil BBB | Stable | 1 Apr 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 1 Apr 2026 | ▼ Downgrade1 notch | Crisil BBB+ → Crisil BBB | — | CRISIL | ₹ 35 Cr. | |
| 13 Nov 2025 | Rating action | Crisil BBB+ | — | CRISIL | ₹ 35 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 12 Nov 2026Upcoming | Financial Results/Other business matters | To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the second quarter and half year ended 30th September, 2026 of the Financial Year 2026-27, and other business matters. |
| 5 Aug 2026 | Financial Results/Other business matters | To consider and approve the unaudited standalone and consolidated financial results of the Company for the first quarter ended 30th June, 2026 of the Financial Year 2026-27, and other business matters. |
| 28 May 2026 | Financial Results/Other business matters | To consider and approve the audited financial results (Standalone and Consolidated) for the fourth quarter and financial year ended March 31, 2026 and other business matters |
| 28 Jan 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 11 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 5 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 30 May 2025 | Financial Results/Other business matters | To consider and approve the audited financial results (Standalone & Consolidated) for the fourth quarter and financial year March 31, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 55 | 61 | 60 | 66 | 77 | 73 | 76 | 71 | 56 | 73 | 71 | 81 |
| Expenses | 44 | 47 | 46 | 56 | 67 | 69 | 64 | 67 | 55 | 69 | 71 | 76 |
| Operating Profit | 11 | 14 | 13 | 10 | 11 | 4 | 13 | 4 | 1 | 3 | 0 | 5 |
| OPM % | 19.7% | 22.5% | 22.5% | 15.4% | 13.7% | 5.4% | 16.5% | 5.9% | 2.1% | 4.3% | 0.2% | 5.8% |
| Other Income | 6 | 2 | −1 | −2 | −4 | 4 | −2 | −2 | 2 | 0 | 3 | −1 |
| Interest | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 16 | 14 | 11 | 7 | 6 | 6 | 10 | 1 | 1 | 2 | 1 | 2 |
| Tax % | 7.9% | 4.8% | 4.9% | 12.1% | 17.4% | 11.7% | 10.6% | 67% | 84.1% | 80.8% | 56.4% | 38.3% |
| Net Profit | 14 | 14 | 11 | 6 | 5 | 5 | 9 | 0 | 0 | 0 | 1 | 1 |
| EPS in Rs | 2.82 | 2.65 | 2.01 | 1.17 | 0.83 | 0.97 | 1.57 | 0.05 | 0.04 | 0.06 | 0.11 | 0.24 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 3%
- 3 Years
- −7%
- TTM
- −6%
- 10 Years
- —
- 5 Years
- −48%
- 3 Years
- −69%
- TTM
- −87%
- 10 Years
- 19%
- 5 Years
- −26%
- 3 Years
- −37%
- TTM
- —
- 10 Years
- —
- 5 Years
- 8%
- 3 Years
- −4%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Balaxi Pharmaceuticals | ₹ 20.26 | ₹ 112 Cr. | 46.2x | 0.5x | 1% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 25.5x | 2.4x | 9.9% | 10.4% |
| Neuland Laboratories | ₹ 18,695.00 | ₹ 23,893 Cr. | 66.1x | 13x | 21.4% | 18% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 27.6x | 5x | 17.2% | 28.7% |
| Unichem Laboratories | ₹ 472.00 | ₹ 3,294 Cr. | 54.9x | 1.5x | 9.8% | 11.5% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 34.1x | 5.4x | 16.7% | 15% |
Management
- Ashish Maheshwari
- Executive Chairman of the Board, Managing Director
- Amol Mantri
- Chief Financial Officer
- Pranav Maheshwari
- Senior Vice President - Business Development
- Mohith Kumar Khandelwal
- Compliance Officer, Company Secretary
- Jignesh Dinesh Kumar Shah
- Finance Controller, Angola
- Ram Chawla
- Country Head, Angola
- Bharat Jawarani
- Sales Head, Dominican Republic
- Manish Jumnani
- Sales Head, Guatemala
Prices are delayed and for information only. Nothing on this page is investment advice.